Want to see PHR full AI Analyst Report?
PHR Stock Chart & Stats
$9.17
$0.87(3.22%)
At close: 4:00 PM EST
$9.17
$0.87(3.22%)
Day’s Range― - ―
52-Week Range$7.77 - $32.76
Previous CloseN/A
Volume173.69K
Average Volume (3M)1.03M
Market Cap
$673.13M
Enterprise Value$595.79M
Total Cash (Recent Filing)$74.71M
Total Debt (Recent Filing)$92.56M
Price to Earnings (P/E)70.4
Beta0.99
Next Earnings
Sep 09, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding61,811,890
10 Day Avg. Volume667,493
30 Day Avg. Volume1,028,127
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda14.04
Forecast
1Y Price Target
$14.00Price Target Upside52.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)0.4
Revenue Forecast (FY)$515.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationPhreesia's recent TTM operating cash flow and $76M free cash flow show durable cash conversion from recurring provider fees and life‑sciences programs. High FCF (~86% of net income TTM) provides lasting flexibility to invest, de‑risk operations, pay down leverage, or fund strategic M&A.
Profitability InflectionThree consecutive quarters of net income and a sharp rise in adjusted EBITDA margin reflect a structural shift from loss to sustainable profitability. If cost actions and AI efficiencies hold, this margin base supports reinvestment into product and sales while reducing reliance on financing for growth.
Scale In Payments & Financing CapacityAn expanded $300M securitization facility and strengthened credit support materially increase capacity to fund payment solutions and scale Access One volumes. This structural funding backbone enables higher managed payments, program reach, and life‑sciences monetization over the medium term.
Bears Say
Decelerating Revenue GrowthSlower top‑line expansion reduces the margin for error in sustaining profitability. With growth down from earlier pace, incremental revenue is less certain to cover fixed tech and compliance costs, making earnings and cash generation more sensitive to client spending cycles and execution.
Thin Operating MarginsVery slim operating profitability means small revenue or cost swings can quickly erase net gains. Maintaining positive net income depends on continued cost discipline and revenue stability; otherwise the company risks margin compression that would reverse recent profitability improvements.
Visibility & Acquisition DependenceMgmt flagged increased variability in Network Solutions commitments and that Payment Solutions growth was materially aided by Access One. Reliance on inorganic lift plus fluctuating client spend undermines multi‑quarter revenue visibility and makes organic growth and margin sustainability harder to predict.
Phreesia News
PHR FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was $7.77 and its highest was $32.76 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $673.13M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Sep 09, 2026 which is in 52 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on May 27, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.039.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.09.
How many shares outstanding does Phreesia have?
Phreesia has 61,811,890 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.05 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went up 3.505%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in PHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (52.67% Upside)
$14.00 (52.67% Upside)
Blogger Sentiment
Neutral
PHR Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.69%
12-Months-Change
Fundamentals
Return on Equity
2.79%
Trailing 12-Months
Asset Growth
66.37%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
PHR Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
PHR Stock 12 Month Forecast
Average Price Target
$14.00
▲(52.67% Upside)
Technical Analysis
Ownership Overview
20.63% Insiders
18.24% Mutual Funds
35.52% Other Institutional Investors
13.46% Public Companies and
Individual Investors